Has the Japanese Biotech Industry valuation changed over the past few years?

Investors are optimistic on the Japanese Biotechnology industry, and appear confident in long term growth rates. The 3-year average PS ratio of 4.9x is lower than the industry's current PS ratio of 6.3x.

How does Japanese Biotech compare with similar industries?

There are no additional sub-industries under this industry.

Japanese (NIKKEI) Biotech Industry Analysis

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Mon, 14 Sep 2026	JP¥989.6b	JP¥156.5b	-JP¥38,337,894,682.00	60.5x	-25.8x	6.3x
Wed, 12 Aug 2026	JP¥895.4b	JP¥159.6b	-JP¥44,216,103,682.00	28.6x	-20.3x	5.6x
Fri, 10 Jul 2026	JP¥836.3b	JP¥159.3b	-JP¥44,566,762,682.00	29x	-18.8x	5.3x
Sun, 07 Jun 2026	JP¥1.0t	JP¥198.8b	-JP¥57,269,138,682.00	45.8x	-17.5x	5.1x
Tue, 05 May 2026	JP¥1.1t	JP¥202.7b	-JP¥49,271,096,682.00	60.7x	-23x	5.6x
Thu, 02 Apr 2026	JP¥1.2t	JP¥202.7b	-JP¥49,460,354,682.00	58.5x	-23.4x	5.7x
Sat, 28 Feb 2026	JP¥1.3t	JP¥200.5b	-JP¥50,373,794,682.00	322.6x	-25.3x	6.3x
Mon, 26 Jan 2026	JP¥1.1t	JP¥198.7b	-JP¥70,406,297,000.00	66x	-16.2x	5.7x
Wed, 24 Dec 2025	JP¥959.1b	JP¥198.7b	-JP¥70,727,642,000.00	51.7x	-13.6x	4.8x
Fri, 21 Nov 2025	JP¥1.1t	JP¥196.3b	-JP¥69,296,079,000.00	51.1x	-15.3x	5.4x
Sun, 19 Oct 2025	JP¥1.1t	JP¥197.7b	-JP¥65,502,224,000.00	62.6x	-16.8x	5.6x
Tue, 16 Sep 2025	JP¥1.2t	JP¥197.7b	-JP¥65,795,565,000.00	67.6x	-18.1x	6x
Thu, 14 Aug 2025	JP¥1.2t	JP¥191.4b	-JP¥67,580,048,000.00	123x	-17.2x	6.1x
Sat, 12 Jul 2025	JP¥1.1t	JP¥218.2b	-JP¥43,671,220,000.00	98.8x	-25.2x	5.1x
Mon, 09 Jun 2025	JP¥1.2t	JP¥214.8b	-JP¥40,595,705,000.00	14.7x	-29.7x	5.6x
Wed, 07 May 2025	JP¥1.1t	JP¥207.8b	-JP¥39,129,850,000.00	15x	-27.5x	5.2x
Fri, 04 Apr 2025	JP¥974.4b	JP¥207.8b	-JP¥39,284,718,000.00	15x	-24.8x	4.7x
Sun, 02 Mar 2025	JP¥1.0t	JP¥207.4b	-JP¥38,725,942,000.00	15x	-26.3x	4.9x
Tue, 28 Jan 2025	JP¥992.6b	JP¥207.3b	-JP¥13,514,452,000.00	20.9x	-73.5x	4.8x
Thu, 26 Dec 2024	JP¥1.0t	JP¥206.4b	-JP¥12,718,809,000.00	21.9x	-82.2x	5.1x
Sat, 23 Nov 2024	JP¥1.1t	JP¥207.5b	-JP¥10,809,446,000.00	20.7x	-98.7x	5.1x
Mon, 21 Oct 2024	JP¥1.1t	JP¥214.3b	-JP¥3,941,502,000.00	21.8x	-285.1x	5.2x
Wed, 18 Sep 2024	JP¥1.0t	JP¥209.0b	-JP¥1,268,229,000.00	16.2x	-814.9x	4.9x
Fri, 16 Aug 2024	JP¥978.3b	JP¥214.0b	JP¥2.3b	12.8x	431x	4.6x
Sun, 14 Jul 2024	JP¥1.1t	JP¥187.7b	-JP¥15,773,047,000.00	95.4x	-68.6x	5.8x
Tue, 11 Jun 2024	JP¥835.9b	JP¥195.7b	-JP¥14,113,284,000.00	96.8x	-59.2x	4.3x
Thu, 09 May 2024	JP¥797.4b	JP¥199.1b	-JP¥14,617,545,000.00	77.6x	-54.6x	4x
Sat, 06 Apr 2024	JP¥756.9b	JP¥194.2b	-JP¥15,456,803,000.00	63.9x	-49x	3.9x
Mon, 04 Mar 2024	JP¥814.8b	JP¥196.2b	-JP¥19,179,997,000.00	65.5x	-42.5x	4.2x
Wed, 31 Jan 2024	JP¥772.8b	JP¥222.3b	-JP¥12,604,827,000.00	18x	-61.3x	3.5x
Fri, 29 Dec 2023	JP¥809.9b	JP¥224.2b	-JP¥12,970,409,000.00	17.4x	-62.4x	3.6x
Sun, 26 Nov 2023	JP¥805.7b	JP¥221.9b	-JP¥12,426,487,000.00	17.4x	-64.8x	3.6x
Tue, 24 Oct 2023	JP¥741.8b	JP¥223.0b	-JP¥14,478,735,000.00	20.6x	-51.2x	3.3x
Thu, 21 Sep 2023	JP¥874.3b	JP¥223.0b	-JP¥14,518,735,000.00	27.9x	-60.2x	3.9x


JP Market	-1.69%
Healthcare	-4.23%
Biotech	2.75%
Biotech	2.75%

Company	Last Price	7D	1Y	Valuation
4588 Oncolys BioPharma	JP¥6.16k	24.4% +JP¥35.6b	891.9%	PS6353.1x
7777 3-D Matrix	JP¥408.00	16.2% +JP¥7.3b	40.7%	PE14.1x
219A Heartseed	JP¥2.44k	8.4% +JP¥4.3b	-34.3%	PE94.4x
4894 Cuorips	JP¥5.82k	8.4% +JP¥3.7b	-22.3%	PS375.6x
2929 Pharma Foods International	JP¥691.00	13.8% +JP¥2.4b	-19.7%	PE10.1x

Announcement • Jun 10

Oncolys BioPharma Receives Full Marketing Approval in Japan for Telomelysin Injection for the Treatment of Esophageal Cancer

Oncolys BioPharma Inc. announced that the Japanese Ministry of Health, Labour and Welfare has granted marketing approval for Telomelysin Injection (generic name: suratadenoturev; development code: OBP-301), an oncolytic adenovirus product, for the treatment of esophageal cancer in patients who are not eligible for curative resection or chemoradiotherapy. Telomelysin is the world’s first oncolytic adenovirus product approved for the treatment of esophageal cancer. The approval was granted as a full marketing approval, rather than conditional or time-limited approval, following MHLW review of data from Oncolys’ pivotal clinical study conducted at 17 sites in Japan. Oncolys submitted the marketing authorization application on December 15, 2025. Telomelysin is designed to selectively replicate in and lyse cancer cells by utilizing telomerase activity, which is highly expressed in many malignant tumors. Through this mechanism, Telomelysin is intended to offer a new treatment option for patients with esophageal cancer who have limited therapeutic alternatives. Under the sales partnership agreement entered into in February 2024, FUJIFILM Toyama Chemical Co. Ltd. will be responsible for the commercialization of Telomelysin in Japan following National Health Insurance price listing. As a result of this approval, Oncolys will receive a milestone payment from FUJIFILM Toyama Chemical, which is expected to be recorded as revenue for the fiscal year ending December 31, 2026. Oncolys also expects to receive the remaining balance of the payment related to product supply during the current fiscal year. This amount will initially be recorded as advances received, or contract liabilities, on Oncolys’ balance sheet and is expected to be recognized as revenue progressively following the commercial launch of Telomelysin. The amounts have not been disclosed. Oncolys plans to launch Telomelysin in Japan in fiscal year 2026 following National Health Insurance price listing. The impact of this approval on Oncolys’ financial results for the current fiscal year is currently under review. Telomelysin is an oncolytic adenovirus designed to selectively replicate in cancer cells through activation of the human telomerase reverse transcriptase promoter. Following intratumoral administration, Telomelysin replicates within cancer cells and induces tumor cell lysis. Oncolys has been developing Telomelysin as a novel cancer therapy, with a focus on indications in which local tumor control and combination with radiotherapy may provide clinical benefit.

Japanese (NIKKEI) Biotech Industry Analysis

Industry Valuation and Performance

Industry Comparison

Top Stock Gainers and Losers

Latest News

New major risk - Revenue and earnings growth

Full year 2026 earnings: EPS exceeds analyst expectations while revenues lag behind

First quarter 2027 earnings released: EPS: JP¥2.36 (vs JP¥6.88 in 1Q 2026)

New minor risk - Market cap size

Heartseed Inc. to Report Q3, 2026 Results on Nov 13, 2026

Japan Tissue Engineering Co., Ltd. to Report Q2, 2027 Results on Oct 30, 2026

BrightPath Biotherapeutics Co., Ltd. to Report Q2, 2027 Results on Nov 13, 2026

We're Keeping An Eye On CanBas' (TSE:4575) Cash Burn Rate

ReproCELL Incorporated to Report Q2, 2027 Results on Nov 12, 2026

AnGes, Inc. announced that it has received ¥2.022905015 billion in funding from Growth Partners Co., Ltd.

Healios K.K. to Report Q3, 2026 Results on Nov 12, 2026

PeptiDream Inc. to Report Q3, 2026 Results on Nov 11, 2026

Second quarter 2026 earnings released: EPS: JP¥2.49 (vs JP¥7.62 loss in 2Q 2025)

SanBio Company Limited to Report Q2, 2027 Results on Sep 14, 2026

TMS Co., Ltd. to Report Q2, 2026 Results on Aug 14, 2026

Oncolys BioPharma Receives Full Marketing Approval in Japan for Telomelysin Injection for the Treatment of Esophageal Cancer